Company Overview: CHINARES PHARMA (03320.HK) reported its interim results for the period ending June 2025, showing a revenue increase of 2.5% year-over-year to RMB131.867 billion.
Profit Decline: The company's net profit decreased by 20.3% year-over-year to RMB2.077 billion, resulting in an earnings per share (EPS) of RMB0.33.
Dividends Declared: An interim dividend per share (DPS) of RMB0.072 was declared, down from RMB0.083 in the same period of 2024.
Market Activity: The stock experienced short selling amounting to $11.07 million, with a short selling ratio of 20.039%.
03320
$4.53+Infinity%1D
Analyst Views on 03320
Wall Street analysts forecast 03320 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 03320 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 03320 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 03320 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 4.530
Low
Averages
High
Current: 4.530
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
